Midwest Financial Partners Investments Inc. Acquires Shares of 2,346 Amgen Inc. $AMGN

Midwest Financial Partners Investments Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,346 shares of the medical research company’s stock, valued at approximately $768,000.

A number of other hedge funds also recently bought and sold shares of AMGN. Kingdom Financial Group LLC. purchased a new position in shares of Amgen during the 4th quarter worth $308,000. Van Hulzen Asset Management LLC raised its holdings in shares of Amgen by 5.2% during the 4th quarter. Van Hulzen Asset Management LLC now owns 4,450 shares of the medical research company’s stock worth $1,456,000 after acquiring an additional 219 shares during the period. Signature Estate & Investment Advisors LLC raised its holdings in shares of Amgen by 1.6% during the 4th quarter. Signature Estate & Investment Advisors LLC now owns 6,360 shares of the medical research company’s stock worth $2,082,000 after acquiring an additional 100 shares during the period. Plan A Wealth LLC raised its holdings in shares of Amgen by 5.7% during the 4th quarter. Plan A Wealth LLC now owns 1,224 shares of the medical research company’s stock worth $401,000 after acquiring an additional 66 shares during the period. Finally, FourThought Financial Partners LLC raised its holdings in shares of Amgen by 1.1% during the 4th quarter. FourThought Financial Partners LLC now owns 31,972 shares of the medical research company’s stock worth $10,465,000 after acquiring an additional 349 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s xaluritamig prostate cancer trial is advancing, which supports the company’s long-term pipeline narrative and could improve investor confidence in future oncology revenue. Amgen Advances Xaluritamig Trial in Hard-to-Treat Prostate Cancer
• Positive Sentiment: Analysts remain constructive on Amgen despite a small target cut, with Piper Sandler reiterating an Overweight rating and other coverage pointing to pipeline strength and sales growth. Amgen Inc. (AMGN): Navellier’s Long-Term Pick on Pipeline Strength and Sales Growth
• Positive Sentiment: Argus lowered its price target to $375 from $400 but kept a Buy rating, reinforcing the view that Amgen still has upside from current levels. Argus adjusts price target on Amgen to $375 from $400, maintains Buy rating
• Neutral Sentiment: Amgen was included in a broad report on the late-stage chronic kidney disease market, which is more of an industry overview than a company-specific catalyst. Late-Stage Chronic Kidney Disease Market Analysis Report 2026-2036
• Negative Sentiment: Amgen’s rare-disease drug Tavneos faced new warning-related scrutiny in Japan after patient deaths, though regulators later allowed new patients to be prescribed the drug again; this may still weigh on sentiment because it highlights safety risk. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths
• Negative Sentiment: A broader Senate bill on maternal health could affect large pharma and biotech companies indirectly through future research, surveillance, and policy changes, but it is not an immediate Amgen-specific driver. New Bill: Senator Elizabeth Warren introduces S. 4550: Maternal Health Pandemic Response Act

Amgen Trading Up 1.8%

NASDAQ AMGN opened at $337.42 on Friday. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The firm has a market cap of $182.10 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 3.33 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a 50 day simple moving average of $345.86 and a 200-day simple moving average of $344.41.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the previous year, the firm posted $4.90 EPS. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.15%.

Analysts Set New Price Targets

A number of research firms recently commented on AMGN. Barclays began coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. UBS Group upped their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Citigroup upped their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Finally, Guggenheim decreased their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $355.19.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.